Login / Signup

Predictive and dynamic signature for anti-angiogenics in combination with PD-1 inhibitor in soft-tissue sarcoma: correlative studies linked to the IMMUNOSARC trial.

David S MouraJesus M Lopez-MartiIva BenesovaCarlos E De AndreaDavide Di LerniaSerena LacerenzaJose L Mondaza-HernandezMarta Martín-RuizMarta Ramirez-CalvoGiovanni GrignaniJavier Martínez TruferoAndres RedondoClaudia María ValverdeSilvia StacchiottiAntonio L PousaJose Antonio Lopez-GuerreroAntonio GutierrezVictor EncinasNadia HindiDario SangioloJose Antonio Lopez-MartinZuzana Ozaniak StrizovaJavier Martín-Broto
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Treatment with sunitinib and nivolumab inflamed the sarcoma microenvironment, increasing CD8+ T cell density and the expression of several genes/ proteins with relevance in the response to PD-1 inhibitors. A molecular signature identified two groups of patients with distinct PFS for the combination of anti-angiogenics plus PD-1 inhibitor.
Keyphrases
  • poor prognosis
  • stem cells
  • clinical trial
  • study protocol
  • randomized controlled trial
  • combination therapy
  • dna methylation
  • transcription factor
  • open label